What is new in the management of Helicobacter pylori?

Irish Journal of Medical Science

Volumn 177, Issue 3, 2008, Pages 185-188

  Egan, B J ^a   O'Connor, H J ^a   O'Morain, C A ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Antimicrobial resistance; Eradication rates; First line treatment; Helicobacter pylori; Indications for treatment; Second line treatment; Treatment failure

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BISMUTH DERIVATIVE; CLARITHROMYCIN; ESOMEPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; RIFABUTIN; TETRACYCLINE;

ADJUVANT THERAPY; ANTIBIOTIC RESISTANCE; CANCER RISK; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERADICATION THERAPY; EUROPE; FECES ANALYSIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IRELAND; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; STOMACH CANCER; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UREA BREATH TEST;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; OMEPRAZOLE; PRACTICE GUIDELINES AS TOPIC; PROBIOTICS; PROTON PUMP INHIBITORS; RIFABUTIN; TETRACYCLINE;

EID: 48549086932     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11845-008-0173-8     Document Type: Review

References (27)

1. Marshall BJ, Warren JR (1983) Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1(8336):1273-1275
2. Coghlan JG, Gilligan D, Humphries H et al (1987) Campylobacter pylori and recurrence of duodenal ulcers - a 12-month follow-up study. Lancet 2(8568):1109-1111
3. Malfertheiner P, Megraud F, O'Morain C et al (2007) Current concepts in the management of Helicobacter pylori infection: The Maastricht III consensus report. Gut 56(6):772-781
4. Lee JM, Deasy E, O'Morain CA (2000) Helicobacter pylori eradication therapy: A discrepancy between current guidelines and clinical practice. Eur J Gastroenterol Hepatol 12(4):433-437
5. Chiba N, Veldhuyzen Van Zanten SJO et al (2002) Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 324(7344):1012-1016
6. Franchini M, Veneri D (2004) Helicobacter pylori infection and immune thrombocytopenic purpura: An update. Helicobacter 9:342-346
7. Huang JQ, Sridhar S, Hunt RH (2002) Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: A meta-analysis. Lancet 359:14-22
8. Gisbert JP, Pajares JM (2004) Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment Pharmacol Ther 20:1001-1017
9. Rogge JD, Wagner DR, Carrico RJ et al (1995) Evaluation of a new urease reagent strip for detection of Helicobacter pylori in gastric biopsy specimens. Am J Gastroenterol 90:1965-1968
10. Egan BJ, Ryan BM, O'Morain CA Test, treat and confirm eradication. BMJ online 13/2/07
11. Saleem A, Dobson M, Thornton O, O'Connor HJ, O'Morain CA ISG. Poster presentation 2006
12. Correa P (1992) Human gastric carcinogenesis: A multistep and multifactorial process - first American Cancer Society Award Lecture on cancer epidemiology and prevention. Cancer Res 52(24):6735-6740
13. Cheung TK, Wong BC (2008) Treatment of Helicobacter pylori and prevention of gastric cancer. J Dig Dis 9(1):8-13
14. Laheij R (2006) Is community treatment of H. pylori feasible?. United European Gastroenterology Week, Berlin
15. Fischbach L, Evans EL (2007) Meta-analysis: The effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 26(3):343-357
16. Hooton C, Dempsey C, Keohane J et al (2006) Helicobacter pylori: prevalence of antimicrobial resistance in clinical isolates. Br J Biomed Sci 63(3):113-116
17. Ford A, Moayyedi P (2003) How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol 17(Suppl B):36B-40B
18. Egan BJ, Katicic M, O'Connor HJ, O'Morain CA (2007) Treatment of Helicobacter pylori. Helicobacter 12(Suppl 1):31-37
19. Lesbros-Pantoflickova D, Corthésy-Theulaz I, Blum AL (2007) Helicobacter pylori and probiotics. J Nutr 137(3 Suppl 2):812S-818S
20. De Bortoli N, Leonardi G, Ciancia E et al (2007) Helicobacter pylori eradication: A randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol 102(5):951-956
21. Cremonini F, Di Caro S, Covino M et al (2002) Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: A parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 97(11):2744-2749
22. Uygun A, Ozel AM, Yildiz O et al (2008) J Gastroenterol Hepatol. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy. J Gastroenterol Hepatol 23(1):42-45
23. Gisbert JP, De la Morena F (2006) Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 23(1):35-44
24. Gisbert JP, Bermejo F, Castro-Fernández M et al (2008) H. pylori study group of the Asociación Española de Gastroenterología. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: A Spanish multicenter study of 300 patients. Am J Gastroenterol 103(1):71-76
25. Van der Poorten D, Katelaris PH (2007) The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 26(11-12):1537-1542
26. Miehlke S, Schneider-Brachert W, Kirsch C et al (2008) One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 13(1):69-74
27. Gisbert JP, Gisbert JL, Marcos S et al (2008) Empirical rescue therapy after Helicobacter pylori treatment failure: A 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 27(4):346-354